Enbrel All Financial Data in US $ (mln)

Word Search (Top 10 - by date)

Samsung Bioepis Receives Positive CHMP Opinion for the First Etanercept Biosimilar in the European Union
Samsung Bioepis (November 20, 2015)
Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles in One-Year Phase 3 Clinical Studies
Samsung Bioepis (November 08, 2015)
Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates
Samsung Bioepis (November 07, 2015)
Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
Merck & Co (November 05, 2015)
Amgen Highlights Data To Be Presented At 2015 American College Of Rheumatology And Association For Rheumatology Health Professionals Annual Meeting
Amgen (November 04, 2015)
CEL-SCI’s Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health
CEL-SCI (November 04, 2015)
Amgen's Third Quarter 2015 Revenues Increased 14 Percent To $5.7 Billion And Adjusted Earnings Per Share (EPS) Increased 18 Percent To $2.72
Amgen (October 28, 2015)
Novartis Delivered Strong Core Margin Expansion (c) and Continued to Strengthen the Pipeline in Q3; on Track for Full-year Guidance
Novartis (October 27, 2015)
Pfizer (October 27, 2015)
Nabriva Therapeutics Hires Will Sargent as Vice President of Commercial Strategy and Investor Relations
Nabriva Therapeutics (October 14, 2015)

Displaying 10 out of a possible 692 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Enbrel
Generic Name:   etanercept
Therapeutic Subcategory:     Other anti-rheumatics
Therapeutic Subcategory:     Anti-virals

Product Sales Summary 2012/13

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic NameGeneric Name Therapeutic Subcategory 2012 2013 2013
Enbrel2 8,496 8,778 +3%
Note: Shaded Cells3

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Enbrel4 429


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product: Enbrel

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now